

NOTIFICATION TO STOCK EXCHANGE
COMPANY STATEMENT

**Biocon Biologics and Yoshindo Expand Access to
Ustekinumab Biosimilar in Japan**

Bengaluru, Karnataka, India, May 21, 2025

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that its commercial partner in Japan, Yoshindo Inc., has launched **Ustekinumab BS Subcutaneous Injection [YD]**, a biosimilar to the reference product Stelara® (ustekinumab). The biosimilar ustekinumab, developed and manufactured by Biocon Biologics, is commercialized and marketed in Japan by Yoshindo Inc.

Ustekinumab, a monoclonal antibody, is approved for the treatment of **psoriasis vulgaris** and **psoriatic arthritis (PsA)**.

In April 2024, the [Company entered into a settlement and licensing agreement](#) with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen) to **commercialize Ustekinumab in Japan** upon regulatory approval. Biocon Biologics' biosimilar Ustekinumab BS Subcutaneous Injection [YD] [was approved by the Pharmaceuticals and Medical Devices Agency \(PMDA\)](#) of Japan in December 2024.

Biocon Biologics has already launched Ustekinumab in the [United States](#) and Europe in February 2025 to help patients manage their chronic conditions.

– Company Spokesperson